We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

Doctors have begun noticing a trend among their colleagues: many have visibly shed pounds, and it's all thanks to drugs like ...